Skip to main content
. 2023 Jan 19;16(2):151. doi: 10.3390/ph16020151

Table 4.

Clinical status of nanocarriers.

Name Description Administration Clinical Trials ID
NanoLithium® NP03 Proof-of-concept study to assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe AD Depositing in the gingivo-jugal groove of each cheek NCT05423522
APH-1105 Study to assess the safety, tolerability, and efficacy of intranasal delivery of APH-1105 for the treatment of mild-to-moderate AD in adults Intranasal NCT03806478